Issues lobbied + lobbyists (4)
HCR — Health Issues
Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.
Lobbyists:- LISA LAYMAN — covered position: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
MED — Medical/Disease Research/Clinical Labs
Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.
Lobbyists:- LISA LAYMAN — covered position: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
BUD — Budget/Appropriations
H.R. 7148/Public Law No: 119-75, psychedelic therapies for treatment of mental health and substance use disorders related to the FY26 budget for the Department of Health and Human Services; FY2027 budget related to psychedelic therapies for treatment of mental health and substance use disorders.
Lobbyists:- LISA LAYMAN — covered position: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)
Government entities lobbied: HOUSE OF REPRESENTATIVES
VET — Veterans
H.R.2623 - Innovative Therapies Centers of Excellence Act of 2025, S. 4220 - Veterans Health Administration Novel Therapeutics Preparedness Act.
Lobbyists:- LISA LAYMAN — covered position: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)
Government entities lobbied: HOUSE OF REPRESENTATIVES